Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 6/20 | 0.56 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.56 |
| ▸ | GLP1R | P43220 | 13/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30918524 | 0.97 | GLP1R (0.58) | OPRM1OPRD1OPRK1GLP1R | |
| SCHEMBL31030934 | 0.96 | GLP1R (0.57) | OPRM1OPRD1OPRK1GLP1R | |
| SCHEMBL30299020 | 0.95 | GLP1R (0.58) | OPRM1OPRD1OPRK1GLP1R | |
| SCHEMBL30080556 | 0.94 | OPRM1 (0.61) | OPRM1OPRD1OPRK1GLP1R | |
| SCHEMBL30407947 | 0.93 | OPRM1 (0.55) | OPRM1OPRD1OPRK1GLP1R | |
| SCHEMBL31467321 | 0.93 | OPRM1 (0.62) | OPRM1OPRD1OPRK1GLP1R | |
| SCHEMBL31256793 | 0.93 | OPRM1 (0.55) | OPRM1OPRD1OPRK1GLP1R | |
| SCHEMBL31062669 | 0.90 | GLP1R (0.65) | OPRM1OPRD1OPRK1GLP1R | |
| SCHEMBL29722072 | 0.90 | GLP1R (0.65) | OPRM1OPRD1OPRK1GLP1R | |
| SCHEMBL30636778 | 0.90 | GLP1R (0.55) | OPRM1OPRD1OPRK1GLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360194-A1 | New Peptides as Potent and Selective GIP Receptor Agonists | SANOFI (FR) | 2024-10-31 | — | — | US | claimed |
| CN-118159552-A | Novel peptides as potent and selective GIP receptor agonists | 赛诺菲 | 2024-06-07 | — | — | CN | claimed |
| CN-115884982-A | Peptides as selective GIP receptor agonists | 赛诺菲 | 2023-03-31 | — | — | CN | claimed |
| US-20240360194-A1 | New Peptides as Potent and Selective GIP Receptor Agonists | SANOFI (FR) | 2024-10-31 | — | — | US | disclosed |
| CN-118159552-A | Novel peptides as potent and selective GIP receptor agonists | 赛诺菲 | 2024-06-07 | — | — | CN | disclosed |
| CN-115884982-A | Peptides as selective GIP receptor agonists | 赛诺菲 | 2023-03-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360194-A1 | New Peptides as Potent and Selective GIP Receptor Agonists | GIPR, GLP1R, GPR119 | OPRM1 154/4885OPRD1 171/4885OPRK1 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.